C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates that degrade disease-causing proteins through targeted protein degradation science. Its lead product candidate, Cemsidomide, is an orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 proteins, currently in Phase 1/2 clinical trials for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also advancing CFT1946, an orally bioavailable BiDAC degrader for BRAF V600 mutants in Phase 1/2 trials for melanoma, colorectal cancer, and other solid tumors, as well as CFT8919, a mutant-selective BiDAC degrader of epidermal growth factor receptor with L858R mutation for non-small cell lung cancer. C4 Therapeutics Inc. maintains strategic collaborations with partners such as Biogen, Roche, Merck KGaA, and others to expand its discovery and development efforts. Founded in 2015 and headquartered in Watertown, Massachusetts, it plays a key role in oncology by pioneering degraders that offer potentially improved efficacy and tolerability over traditional inhibitors.